Addressing metabolite safety during first-in-man studies using 14C-labeled drug and accelerator mass spectrometry

Bioanalysis

Volumn 2, Issue 7, 2010, Pages 1315-1324

  Lappin, Graham ^a   Seymour, Mark ^a  

^a Xceleron Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CARBON; DRUG;

AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DOSIMETRY; DRUG METABOLISM; DRUG SAFETY; HALF LIFE TIME; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; ISOTOPE ANALYSIS; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRACTICE GUIDELINE; PROCESS DEVELOPMENT; RADIOISOTOPE DECAY; REVIEW; SENSITIVITY ANALYSIS; ANIMAL; CHEMISTRY; METABOLISM; METHODOLOGY; TOXICITY TESTING;

ANIMALS; CARBON RADIOISOTOPES; HUMANS; ISOTOPE LABELING; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 79952495863     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.87     Document Type: Review

References (27)

1. Caldwell J. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol. Lett. 64-65, 651-659 (1992). (Pubitemid 23018810)
2. Eaton DL, Gallagher EP. Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34, 135-172 (1994).
3. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35(4), 325-361 (2005). (Pubitemid 40691298)
4. US FDA. Guidance for industry: safety testing of drug metabolites. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research (CDER), Rockville, MD, USA (2008).
5. ICH topic M3 note for guidance on nonclinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95 (2009).
6. Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22(2), 243-256 (2009).
7. Garner RC, Lappin G. The phase 0 microdosing concept. Chem. Res. Toxicol. 61(4), 367-370 (2006).
8. Lappin G, Garner C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
9. Madan A, O'Brien Z, Wen J et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Chem. Res. Toxicol. 67(3), 288-298 (2008).
10. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 nonnucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J. Clin. Pharmacol. 49(12), 1408-1416 (2009).
11. Espina R, Yu L, Wang J et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 22(2), 299-310 (2009).
12. Vishwanathan K, Babalola K, Wang J et al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22(2), 311-322 (2009).
13. Baillie TA. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem. Res. Toxicol. 22(2), 263-266 (2009).
14. Dear GJ, Roberts AD, Beaumont C, North SE. Evaluation of preparative high-performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876(2), 182-190 (2008).
15. Leclercq L, Cuyckens F, Mannens GS et al. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22(2), 280-293 (2009).
16. Ramanathan R, Zhong R, Blumenkrantz N, Chowdhury SK, Alton KB. Response normalized liquid chromatography nanospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 18(10), 1891-1899 (2007). (Pubitemid 47419352)
17. Whitby B. Quantitative whole body autoradiography. In:Radiotracers in Drug Development . Lappin G, Temple S (Eds).Taylor Francis CRC Press, FL, USA (2006).
18. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6(10), 991-1007 (2000). (Pubitemid 30439022)
19. Vogel JS, Giacomo JA, Schulze-König T et al. Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical 14C measurements. Bioanalysis 2(3), 455-468 (2010).
20. Yasui-Furukori N, Saito M, Inoue Y et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur. J. Clin. Pharmacol. 63(1), 51-56 (2007). (Pubitemid 46025473)
21. Young GC, Corless S, Felgate CC, Colthup PV. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer - fitness for purpose in bioanalysis. Rapid Commun. Mass Spectrom. 22(24), 4035-4042 (2008).
22. Yamane N, Takami T, Tozuka Z et al. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab. Pharmacokinet. 24(4), 389-403 (2009).
23. Scheiner S. Calculation of isotope effects from first principles. Biochim. Biophys. Acta 1458(1), 28-42 (2000). (Pubitemid 30254249)
24. Schmid J, Busch U, Trummlitz G et al. Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotica 25(11), 1219-1236 (1995).
25. Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33(10), 1409-1417 (2005). (Pubitemid 41323986)
26. Rescigno A. Area under the curve and bioavailability. Pharmacol. Res. 42(6), 539-540 (2000).
27. Lappin G. Radioactivity and Radiotracers. Lappin G, Temple S (Eds).Taylor and Francis, Boca Raton, FL, USA (2006).